A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California cancer consortium study

Thehang H. Luu, Robert J. Morgan, Lucille Leong, Dean Lim, Mark McNamara, Jana Portnow, Paul Frankel, David D. Smith, James H. Doroshow, David R Gandara, Ana Aparicio, George Somlo, Carol Wong

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Purpose: The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer. The secondary goals included assessment of time to progression, evaluation of toxicities, and overall survival. Experimental Design: From June 2005 to March 2006, 14 patients received vorinostat, 200 mg p.o., twice daily for 14 days of each 21 day cycle. Response and progression were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Results: The median age for all patients was 60.5 years (range, 37-88). Eight patients were estrogen receptor and/or progesterone positive, four were Her-2 positive. Sites of metastatic disease included brain, liver, lungs, bones, pelvis, pleura, chest wall, and distant lymph nodes. Patients received a median of 1.5 prior (range, 0-2) chemotherapeutic regimens for metastatic disease. Fatigue, nausea, diarrhea, and lymphopenia were the most frequent clinically significant adverse effects. The median number of cycles delivered was 2 (range, 1-20). There were no complete or partial responses, andt he study was terminated after the first stage; however, 4 patients were observed with stable disease with time to progression of 4, 8, 9, and 14 months. The median number of months that patients received treatment on this study was 1.7 (range, 0.5-14). Conclusions: Although not meeting the RECIST response criteria for adequate single-agent activity, the observed tolerable toxicities and the potential for clinical benefit in terms of stable disease suggest that further assessment of vorinostat as a part of combination therapy with either chemotherapeutic or targeted agents in metastatic breast might be undertaken.

Original languageEnglish (US)
Pages (from-to)7138-7142
Number of pages5
JournalClinical Cancer Research
Volume14
Issue number21
DOIs
StatePublished - Nov 1 2008

Fingerprint

Breast Neoplasms
Neoplasms
Lymphopenia
Pleura
Brain Diseases
Thoracic Wall
vorinostat
Pelvis
Estrogen Receptors
Nausea
Fatigue
Progesterone
Diarrhea
Breast
Research Design
Lymph Nodes
Bone and Bones
Lung
Survival
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer : A California cancer consortium study. / Luu, Thehang H.; Morgan, Robert J.; Leong, Lucille; Lim, Dean; McNamara, Mark; Portnow, Jana; Frankel, Paul; Smith, David D.; Doroshow, James H.; Gandara, David R; Aparicio, Ana; Somlo, George; Wong, Carol.

In: Clinical Cancer Research, Vol. 14, No. 21, 01.11.2008, p. 7138-7142.

Research output: Contribution to journalArticle

Luu, TH, Morgan, RJ, Leong, L, Lim, D, McNamara, M, Portnow, J, Frankel, P, Smith, DD, Doroshow, JH, Gandara, DR, Aparicio, A, Somlo, G & Wong, C 2008, 'A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California cancer consortium study', Clinical Cancer Research, vol. 14, no. 21, pp. 7138-7142. https://doi.org/10.1158/1078-0432.CCR-08-0122
Luu, Thehang H. ; Morgan, Robert J. ; Leong, Lucille ; Lim, Dean ; McNamara, Mark ; Portnow, Jana ; Frankel, Paul ; Smith, David D. ; Doroshow, James H. ; Gandara, David R ; Aparicio, Ana ; Somlo, George ; Wong, Carol. / A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer : A California cancer consortium study. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 21. pp. 7138-7142.
@article{4b73a9274546407cb5f695430a0bcb16,
title = "A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California cancer consortium study",
abstract = "Purpose: The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer. The secondary goals included assessment of time to progression, evaluation of toxicities, and overall survival. Experimental Design: From June 2005 to March 2006, 14 patients received vorinostat, 200 mg p.o., twice daily for 14 days of each 21 day cycle. Response and progression were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Results: The median age for all patients was 60.5 years (range, 37-88). Eight patients were estrogen receptor and/or progesterone positive, four were Her-2 positive. Sites of metastatic disease included brain, liver, lungs, bones, pelvis, pleura, chest wall, and distant lymph nodes. Patients received a median of 1.5 prior (range, 0-2) chemotherapeutic regimens for metastatic disease. Fatigue, nausea, diarrhea, and lymphopenia were the most frequent clinically significant adverse effects. The median number of cycles delivered was 2 (range, 1-20). There were no complete or partial responses, andt he study was terminated after the first stage; however, 4 patients were observed with stable disease with time to progression of 4, 8, 9, and 14 months. The median number of months that patients received treatment on this study was 1.7 (range, 0.5-14). Conclusions: Although not meeting the RECIST response criteria for adequate single-agent activity, the observed tolerable toxicities and the potential for clinical benefit in terms of stable disease suggest that further assessment of vorinostat as a part of combination therapy with either chemotherapeutic or targeted agents in metastatic breast might be undertaken.",
author = "Luu, {Thehang H.} and Morgan, {Robert J.} and Lucille Leong and Dean Lim and Mark McNamara and Jana Portnow and Paul Frankel and Smith, {David D.} and Doroshow, {James H.} and Gandara, {David R} and Ana Aparicio and George Somlo and Carol Wong",
year = "2008",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-08-0122",
language = "English (US)",
volume = "14",
pages = "7138--7142",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer

T2 - A California cancer consortium study

AU - Luu, Thehang H.

AU - Morgan, Robert J.

AU - Leong, Lucille

AU - Lim, Dean

AU - McNamara, Mark

AU - Portnow, Jana

AU - Frankel, Paul

AU - Smith, David D.

AU - Doroshow, James H.

AU - Gandara, David R

AU - Aparicio, Ana

AU - Somlo, George

AU - Wong, Carol

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Purpose: The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer. The secondary goals included assessment of time to progression, evaluation of toxicities, and overall survival. Experimental Design: From June 2005 to March 2006, 14 patients received vorinostat, 200 mg p.o., twice daily for 14 days of each 21 day cycle. Response and progression were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Results: The median age for all patients was 60.5 years (range, 37-88). Eight patients were estrogen receptor and/or progesterone positive, four were Her-2 positive. Sites of metastatic disease included brain, liver, lungs, bones, pelvis, pleura, chest wall, and distant lymph nodes. Patients received a median of 1.5 prior (range, 0-2) chemotherapeutic regimens for metastatic disease. Fatigue, nausea, diarrhea, and lymphopenia were the most frequent clinically significant adverse effects. The median number of cycles delivered was 2 (range, 1-20). There were no complete or partial responses, andt he study was terminated after the first stage; however, 4 patients were observed with stable disease with time to progression of 4, 8, 9, and 14 months. The median number of months that patients received treatment on this study was 1.7 (range, 0.5-14). Conclusions: Although not meeting the RECIST response criteria for adequate single-agent activity, the observed tolerable toxicities and the potential for clinical benefit in terms of stable disease suggest that further assessment of vorinostat as a part of combination therapy with either chemotherapeutic or targeted agents in metastatic breast might be undertaken.

AB - Purpose: The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer. The secondary goals included assessment of time to progression, evaluation of toxicities, and overall survival. Experimental Design: From June 2005 to March 2006, 14 patients received vorinostat, 200 mg p.o., twice daily for 14 days of each 21 day cycle. Response and progression were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Results: The median age for all patients was 60.5 years (range, 37-88). Eight patients were estrogen receptor and/or progesterone positive, four were Her-2 positive. Sites of metastatic disease included brain, liver, lungs, bones, pelvis, pleura, chest wall, and distant lymph nodes. Patients received a median of 1.5 prior (range, 0-2) chemotherapeutic regimens for metastatic disease. Fatigue, nausea, diarrhea, and lymphopenia were the most frequent clinically significant adverse effects. The median number of cycles delivered was 2 (range, 1-20). There were no complete or partial responses, andt he study was terminated after the first stage; however, 4 patients were observed with stable disease with time to progression of 4, 8, 9, and 14 months. The median number of months that patients received treatment on this study was 1.7 (range, 0.5-14). Conclusions: Although not meeting the RECIST response criteria for adequate single-agent activity, the observed tolerable toxicities and the potential for clinical benefit in terms of stable disease suggest that further assessment of vorinostat as a part of combination therapy with either chemotherapeutic or targeted agents in metastatic breast might be undertaken.

UR - http://www.scopus.com/inward/record.url?scp=58149242889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149242889&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-0122

DO - 10.1158/1078-0432.CCR-08-0122

M3 - Article

C2 - 18981013

AN - SCOPUS:58149242889

VL - 14

SP - 7138

EP - 7142

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -